MLR Review vs Copy Approval: US and UK Promotional Review, Translated
Updated 2026-07-13 · markdown version
US "MLR review" and UK "copy approval" are the same job with different law behind it. In the US, promotional material is reviewed by an internal Medical-Legal-Regulatory committee and submitted to FDA's OPDP on Form 2253 at time of first use. In the UK, material must be certified before use under the ABPI Code (Clause 8 in the 2024 Code, in force 1 October 2024; formerly Clause 14 in the 2019 Code) by a final medical signatory — a legally accountable, named individual. Same intent, very different accountability model.
The translation table
| Concept | US | UK / EU |
|---|---|---|
| The review process | MLR (medical-legal-regulatory) review; promotional review; PRC | Copy approval; certification & examination; "med legal" review |
| The approving act | MLR approval (committee consensus) | Certification — a specific, legally meaningful act under ABPI Code Clause 8 (2024) |
| Who signs | Committee members per SOP | Final medical signatory — UK-registered physician or pharmacist, personally accountable |
| Regulator / code body | FDA (OPDP division) | MHRA (statutory); PMCPA administering the ABPI Code (self-regulatory) |
| Submission to regulator | FDA Form 2253 at first use | No direct 2253 analog; complaints route through PMCPA |
| Safety text | Fair balance; ISI (Important Safety Information); PI | SmPC (Summary of Product Characteristics); PI |
| Linking claims to evidence | Claims annotation; annotated references; substantiation | Referenced copy; annotation |
| Claim inventory | Claims matrix; claims library; core claims document | Claims matrix |
What actually differs (beyond vocabulary)
Accountability shape. The US model distributes responsibility across a committee and post-hoc FDA enforcement (OPDP letters). The UK model concentrates it: the final medical signatory personally certifies that the material complies — a role with no US equivalent — which makes UK signatories famously conservative and UK copy approval a personal-risk decision, not just a process step.
Timing of regulator involvement. Form 2253 means FDA sees US material when it launches. In the UK, PMCPA involvement is typically complaint-driven (often by competitors), so the certification step is the gate.
Safety-text construct. "Fair balance" and ISI are FDA constructs about proportionate risk presentation. The EU/UK anchor is the SmPC — claims must be consistent with it, and UK material carries prescribing information per the Code.
Why this matters for tooling and content
Teams and writers working both markets constantly translate: a "claims annotation" workflow must produce what a US reviewer calls annotated references and a UK signatory calls referenced copy — same locators (page/column/paragraph of the substantiating passage), different sign-off ceremony downstream. Any tool that treats substantiation as first-class travels across both regimes; anything built purely around US committee workflow will feel alien to a UK certification process, and vice versa. (This is deliberate in Claims: the substantiation layer — claim ↔ evidence locator — is regime-neutral; what changes per market is who signs and what gets filed.)
One practical rule for cross-market writers: keep the claims matrix regime-tagged. A claim approved against US labeling is not automatically usable under the SmPC, and the fastest way to fail a UK certification is to import a US deck's claims wholesale.